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This work reports the development of a simple and rapid electrochemical immunosensor for 
the determination of breast cancer biomarker Cancer Antigen 15-3 (CA15-3). Disposable 
and cost-effective chips, consisting of gold screen-printed electrodes (AuSPEs), were used 
to develop the portable electrochemical devices for monitoring the biomarker in point-of-
care (PoC), under clinical context. 
The biosensor preparation consisted of two simple steps. First, a self-assembled monolayer 
(SAM) of mercaptosuccinic acid (MSA) was formed at the AuSPE surface. Then, the 
CA15-3 antibody was covalently bound to the carboxylic groups standing at the electrode 
surface using EDC/NHS chemistry. 
The performance of the developed immunosensor was evaluated by assessing the sensor 
sensitivity, linear response interval, selectivity and detection limit (LOD). The developed 
immunosensor provided a wide linear concentration range (from 1.0 to 1000 U mL
-1
) and 
low detection levels were achieved (LOD of 0.95 U mL
-1
), enabling the sensitive detection 
of the cancer biomarker at clinically relevant levels, using square wave voltammetry 
(SWV) as electroanalytical technique. Moreover, selectivity studies performed against 
other cancer biomarkers (CA 125 and CA 19-9) revealed that the antibody has high 
selectivity for CA15-3 antigen. The immunosensor was applied to the quantification of 
CA15-3 in artificial serum samples with satisfactory results. 
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In 2018, cancer was responsible for 9.6 million deaths, being the second leading cause of 
death in the world. Among all cancer diseases, breast cancer is the third most common 
cancer, with an incidence level of 11.6 % and a mortality rate of 6.6 %, thus, affecting 
millions of women worldwide [1]. 
Cancer biomarkers play an important role in disease screening and treatment follow-up. 
The Carbohydrate Antigen 15-3 (CA 15-3) antigen, a member of the mucin-1 (MUC-1) 
family of glycoproteins, is the most widely used serum marker for breast cancer, being used 
in the detection of metastases and follow-up of the women with breast cancer [2, 3]. The 
normal level of this biomarker in the serum is lower than 30 U mL
-1
 but, if the total CA15-3 
level serum significantly increases, this may be indicative of breast cancer disease [3, 4]. 
Therefore, simple, sensitive and reliable methodologies for CA 15-3 detection are 
currently required for the early disease diagnosis and patient response to treatment.  
Most common methods for determining CA15-3 biomarker rely on immunoassays, manly 
through ELISA tests [5, 6]. Meanwhile, other  immunoassays emerged on the literature, 
differing only in the approach signal transduction, such as chemiluminescence [7, 8], 
electrochemiluminescence [9, 10], fluorescence [11, 12], surface-enhanced raman 
spectroscopy (SERS) [13] and electrochemical readout [14-20]. However, these 
immunosensor usually requires labels and/or secondary antibodies for signal amplification, 
making detection procedures complicated, time-consuming, very dependent on laboratory 
instrumentation and rather expensive. Thus, the development of novel simple, fast and cost-
effective devices for sensitive detection of CA15-3 biomarker, suitable for point-of-care 
(PoC) analysis, is currently a demand. 
In this work, we suggest a novel cheap and disposable electrochemical immunosensor, 
having simple and rapid construction, that can quickly detect the target biomarker in PoC. 
Disposable and cost-effective chips, consisting of gold screen-printed electrodes (AuSPEs), 
were used to develop the portable electrochemical devices. Electrochemical signals of 
specific antibody-antigen interaction were easily transduced by performing electrochemical 












reporting system. The basic features of the proposed based immunosensor are illustrated in 
Scheme 1.  
To build the sensor platforms, a self-assembled monolayer (SAM) of mercaptosuccinic acid 
(MSA) was initially deposited on the surface of a AuSPE to form a narrow carboxylic-acid-
terminated monolayer [21, 22]. Then, the CA 15-3 antibody was coupled to the carboxylic 
groups standing at the electrode surface through NHS/EDC method [23, 24] (see Scheme 
2). In order to evaluate the performance of the electrochemical immunosensor, a systematic 
investigation of several analytical parameters (such as sensitivity, dynamic linear range, 
LOD and selectivity) was performed in buffer solution. After that, the developed 
immunosensor was applied for the determination of the CA 15-3 biomarker in artificial 
serum samples.  
 
 
Scheme 1. Schematic representation showing the different steps involved in the 















Scheme 2. Schematic representation of the procedure for CA 15-3 antibody immobilization 
on the AuSPE surface. 
 




The electrochemical data were recorded with a computer-controlled potentiostat Autolab 
PGSTAT20 (Eco Chemie, Netherlands), controlled by the NOVA 2.4.1 software. Gold 
screen-printed electrodes (AuSPEs, 4 mm diameter, DRP-220AT, DropSens, Merck) were 
used as sensor platforms. The AuSPEs were connected to the potentiostat by means of a 
suitable box, also bought from DropSens (Merck). All experiments were carried out at 
room temperature. 
The SPR experiments were conducted using a SPR Autolab ESPRIT (KEI bv, The 
Netherlands) controlled by KEI SPR Data Acquisition software (version 4.4). Prior to the 
SPR experiments, the flat glass disks coated with a thin gold film (≈50 nm, KEI bv, the 
Netherlands) were washed thoroughly with pure water and ethanol, followed by drying 
under N2 flow. The SPR gold disks were then placed over the half-cylinder glass prism 
covered with a thin layer of refractive-index-matching oil and stand positioned inside the 
equipment in a Kretschmann optical configuration to begin the measurements of the SPR 












constant and reproducible by using a Julabo F32-HE (Germany) water bath. All 
experiments were carried out at 25.0 °C. 
 
2.2 Reagents and solutions 
 
MUC-1 antigen (10.9 kU mL
-1
, American Research Products), anti-mucin 1 rabbit 
polyclonal antibody (anti-CA15-3, St John´s Laboratory), potassium ferricyanide 
(K3[Fe(CN)6], Merck), potassium ferrocyanide trihydrate (K4[Fe(CN)6], Merck), sodium 
chloride (Panreac), sodium hydrogen carbonate (Merck), bovine serum albumin (BSA, 
≥98%, Sigma-Aldrich), mercaptosuccinic acid (MSA, ≥98%, Merck), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC, 98+%, Alfa Aesar), N-
hydroxysuccinimide (NHS, 98%, Aldrich), ethanolamine (EA, ≥98%, Sigma-Aldrich), 
sodium sulfate (Na2SO4, Sigma-Aldrich), sodium dihydrogen phosphate (Sigma-Aldrich), 
sodium hydrogen phosphate (Sigma-Aldrich), sodium acetate (Sigma-Aldrich), acetic acid 
(Sigma-Aldrich) were used as received.  
Water purified with a Milli-Q purification system (Millipore, resistivity > 18 MΩ.cm) was 
used for cleaning and solutions preparation. 




) were prepared in 10 mmol L
-1
 
acetate buffer solution (pH 4.0) and stored at -20 °C if not in use. Less concentrated 
standards were prepared by suitable dilutions of this solution, in the same buffer.  
Artificial serum solution used had the following composition: 7.01 g L
-1
 NaCl, 1.68 g L
-1
 
NaHCO3 and 30 g L
-1
  BSA (pH 7.3) [25].  
 
2.3 Fabrication of immunosensor 
 
The AuSPE was first cleaned with pure water, acetone and ethanol. Then, the chip was 
electrochemically cleaned in a 0.5 mol L
-1
 sulfuric acid solution using cyclic voltammetry 
(CV), applied between 0 and 1.25 V, with a 0.1 V s
-1
 scan rate, until the voltammogram 
becomes stable (approximately 12 cycles). Then, the AuSPE was thoroughly rinsed with 












To sensor platforms were prepared by simple immobilization of bioreceptors over a pre-
formed SAM using EDC/NHS chemistry (see Scheme 2). Firstly, the working area of the 
AuSPE was incubated with a 10 mmol L
-1
 MSA aqueous solution overnight to build the 
SAM due to the strong interaction between the thiol group (-SH) and the gold surface [21, 
22]. After the SAM formation, the AuSPE was rinsed with pure water and then dried under 
a nitrogen stream. Then, the working area of the AuSPE was incubated with a 10 mmol L
-1
 
equimolar mixture of NHS and EDC [23, 24] for 30 min, followed by rinsing with PBS and 
surface drying. After that, the electrode working area was incubated with a solution of 
CA15-3 antibody (prepared in 10 mmol L
-1
 acetate buffer, pH 4.0) for 90 min, at 4 °C. 
After antibody immobilization, the chip surface was rinsed with acetate buffer, followed by 
surface drying. Finally, the remaining reactive sites were blocked by incubating the sensor 
surface with a 10 mmol L
-1
 ethanolamine solution (pH 8.0) for 30 min. After surface 
washing and drying, the resulting modified chip was stored at 4 °C until use. 
 
2.4 Electrochemical measurements 
 
The electrochemical measurements were carried out in a 5 mmol L
-1





, dissolved in 0.1 mol L
-1
 Na2SO4 as electrolyte solution. 
Preliminary experiments revealed that higher peak currents were achieved in Na2SO4 
relatively to PBS (see Fig. S1, SI).   In SWV measurements, the potential was scanned from 
-0.30 to 0.40 V, at a frequency of 10 Hz, with an amplitude of 50 mV and a step potential 
of 2 mV. 
 
2.5 Calibration curves and determination of CA 15-3 in artificial serum 
  
Detection studies were performed by incubating the sensing platforms for 30 min with CA 
15-3 standard solutions (ranging from 0.10 to 1000 U mL
-1
, prepared in 10 mmol L
-1
 
acetate buffer, pH 4.0), followed by electrochemical measurements in the presence of the 
selected redox probe couple. Calibration curves were built by plotting the redox probe peak 
current (Ipeak) values obtained from the SWV measurements against the logarithmic of 












To perform the detection of CA15-3 in artificial serum, serum samples were previously 
diluted 20 times in acetate buffer and then spiked with known amounts of CA15-3 (from 
0.30 to 400 U mL
-1
). All assays were conducted in triplicate. 
 
3. Results and Discussion 
 
3.1 Step-by-step fabrication of the immunosensor 
 
In this work, the immunosensor stability and improved response relied on successful 
modification of the electrode surface concerning the immobilization of biorecognition 
element. Preliminary studies were performed for optimization of experimental conditions 
(association buffer composition, pH, antibody concentration, reaction times, etc.) for the 
effective antibody immobilization at the chip surface (see Fig. S2, SI). Two CA 15-3 
antibody solutions (diluted to concentration levels of 50 and 20 µg mL
-1
) in buffer solutions 
10 mmol L
-1 
PBS pH 7.2 and 10 mmol L
-1
 acetate buffer pH 4.0 were tested. After 
performing the electrochemical experiments, an optimal CA15-3 antibody concentration of 
20 µg mL
-1
, prepared in low ionic strength acidic buffer solution (10 mmol L
-1
 Na-acetate 
buffer, at pH 4.0) as association buffer, was selected for the immunosensor preparation. 
The results obtained suggested that some of the unreacted carboxylic acid groups, after 
EDC/NHS activation, remained negatively charged at the SAM surface (pKa values of 
MSA lie in the range 3–5 [26, 27]) contributing to pre-concentrate the positively charged 
amino acid residues in the CA15-3 antibody. Furthermore, electrostatic attraction in low 
ionic strength medium was reported in the literature as key mechanism for immobilization 
of proteins on the biosensing surfaces [28-30]. By opposition, the use of the high ionic 
strength buffers does not benefit from electrostatic attraction of antibodies to the sensing 
surface since hydrophobic mechanisms dominates [31], thus, decreasing the amount of 
bioreceptors immobilized. 
All surface modifications were followed by electrochemical measurements in the presence 
of [Fe(CN)6]
3−/4−  
redox probe solution, as shown in Fig. 1A. The estimated peak current 
(Ipeak) values are resumed in Table S1 (SI). Furthermore, with 10 mmol L
-1
 MSA solution, 












sensor surface [22]. After SAM activation with a solution of NHS/EDC, the CA15-3 
antibody was immobilized on the AuSPE surface via covalent bond with the available 
unstable esters groups [24], causing an barrier to the diffusional redox probe, thus, 
decreasing the measured peak current. Finally, the remaining unreacted active sites were 
blocked by reaction with ethanolamine [24], leading to a further decrease o redox probe 
peak current.  
Furthermore, the antibody immobilization procedure used in this work was also evaluated 
by SPR technique. During the SPR measurements, all buffers and solutions were 
automatically injected into the measuring channel while monitoring the angle changes 
occurring at the dielectric thin metal film [32, 33]. The real-time step-by-step construction 
of the immunosensor on the SPR gold chips is shown in Fig. 1B. The sensorgram profile 
achieved confirms the electrochemical data collected about the successful immobilization 
of the CA 15-3 antibody at the gold substrates under the previously optimized experimental 
conditions. After the injection of the CA 15-3 antibody, the overall angle shift prior to the 
surface deactivation with ethanolamine (step 7) is of about 400 mº, which corresponds to an 
































prepared in 0.1 mol L
-1
 Na2SO4 electrolyte solution, after each modification step occurring 
at the AuSPE surface. B) SPR sensor response to the immobilization of CA 15-3 antibody 
on the Au sensor surface, previously modified with MSA SAM. Step 1: injection of 10 
mmol L
-1
 PBS, pH 7.4, for 120 s (baseline); Step 2: activation of MSA SAM with a mixture 
of EDC/NHS (50 mmol L
-1
, in water) for 300 s; Step 3: wash with PBS for 30 s (baseline); 
Step 4: immobilization of CA 15-3 antibody (20 µg mL
-1
, in 10 mmol L
-1
 acetate buffer 
solution, pH 4.0) for 900 s; Step 5: wash with PBS for 90 s (baseline); Step 6: deactivation 
of unreacted esters with ethanolamine (1 mol L
-1
, pH 8.0) for 600 s; Step 7: wash with PBS 
for 30 s (baseline); Step 8: wash with PBS, containing 0.1% SDS, for 120 s; Step 9: wash 
with PBS for 30 s (baseline). 
 
3.2 Optimization of the immunoreaction  
 
For comprehensive understanding of antigen binding capacity for immobilized antibodies 
as function of medium pH, the analytical response of the developed immunosensor was 
evaluated at different pH values. The electrochemical signals, obtained from SWVs 
recorded (see Fig. S3, SI) after incubating the sensor surface with several CA 15-3 
solutions (from 0.01 to 100 U mL
-1
) prepared in buffer solution at pH 7.2 and at pH 4.0, are 
shown in Fig. 2. The decrease of the redox probe peak current was more pronounced for 
antigen solutions prepared at pH 4.0 relatively to physiological pH for the several 
concentrations of biomarker tested. Thus, more acid medium pH seems to improve the 












charged protein (isoelectric point of CA 15-3 protein is predicted to be between 3 and 5 
[35]) and the antibody binding sites, which are expected to be negatively charged. 
Therefore, 10 mmol L
-1




Fig. 2. Redox probe peak current obtained from the SWV measurements, performed in the 




, after surface incubation with different CA 15-3 
solutions (from 0.01 to 100 U mL
-1
) prepared in 10 mmol L
-1
 PBS pH 7.2 and 10 mmol L
-1
 





The formation of the immunocomplex between immobilized CA 15-3 antibody and the CA 
15-3 antigen in solution was also studied in real-time by SPR. The sensorgrams collected 
for the various concentrations of CA 15-3 tested (from 0.10 to 500 U mL-1), prepared in 
acetate buffer solution (pH 4.0), are depicted in Fig. 3.  As can be seen in the figure, the 












The SPR angle variation increased with the increasing concentration of CA 15-3. Similar 
studies were performed for CA 15-3 dissolved in PBS at pH 7.2, however, no appreciable 
angle change was observed, except for the higher concentration level of antigen (data not 




Fig. 3. Real-time SPR monitoring of the interaction between immobilized antibody on SPR 
gold substrates and CA 15-3 in solution. The concentrations of CA 15-3 tested ranged from 
0.10 to 500 U mL
-1
.  
Line 1: baseline collected in 10 mmol L
-1
 PBS, pH 7.4, for 60 s;  
Line 2: real-time monitoring of the antigen-antibody interaction for 15 min;  
Line 3: surface wash with 10 mmol L
-1
 PBS, pH 7.4, for 60 s (return to baseline); For 
comparison, the response obtained after injection of association buffer (10 mmol L
-1
 acetate 
buffer solution, pH 4.0, without CA 15-3) into the measuring channel (dashed line) is also 
shown in the figure;  
Line 4: surface regeneration after wash with glycine-HCl buffer solution (pH 2.0) for 300 s;  
Line 5: wash with 0.010 mol L
-1
















3.3 Analytical response of the electrochemical immunosensor 
 
In order to study the analytical performance of the developed immunosensor, the AuSPE 
surface was incubated with solutions with increasing concentration of CA15-3 (from 0.010 
and 1000 U mL
-1
, in 10 mmol L
-1
 acetate buffer, pH 4.0) for 30 min, followed by 
electrochemical measurements in the presence of the biocompatible reporting system. SWV 
was selected as electroanalytical technique to quantify CA15-3 biomarker due to its high 
sensitivity to surface-confined electrode reactions and fast data acquisition (few seconds 
only) [36, 37].  
The voltammograms obtained for the several standard solutions tested are represented in 
Fig 4. A decrease of the redox probe peak current with increasing CA15-3 concentration 
was observed due to the cumulative immunecomplex formation at the sensor surface which 
increasingly hinders the redox probe diffusional behavior. Moreover, the SWV peak current 
was represented as a function of the logarithm of CA 15-3 concentration, as shown in the 
inset of Fig. 4, and a linear pattern was observed for concentrations between 1.0 and 1000 
U mL
-1
. A limit of detection (LOD) of 0.95 U mL
-1
 was estimated according to the IUPAC 
recommendations for ion-selective electrodes, where log(C) is used [38]. Thus, the 
developed immunosensor had a wide range of linearity, allowing direct analysis of CA 15-3 
breast cancer biomarker above and below its cut-off value (30 U mL
-1
 [3]). 
The analytical features of the developed immunosensor was also compared with other 
detection approaches reported in the literature (see Table S2, SI). The detection levels 
(LOD) achieved by the developed immunosensor was of the same order of magnitude of 
most of reported methodologies, including commercially available ELISA tests, while it 
had the widest dynamic linear concentration working range for CA 15-3 detection. 
Nonetheless, it is important to remark that most of these techniques are not label-free (as 
for the biosensor of this work) since they make use of either secondary antibodies and/or 
metal/magnetic NPs or nanocomposites, to push sensitivity up and reduce, in turn, detection 
limit. For example, although FRET immunosensing [39] allowed the ultrasensitive 
detection of CA15-3 (LOD of 0.9 µU mL
-1












as donor fluorescence and AuNPs labeled PAMAM-Dendrimer/aptamer were used as 
quencher. In another work,  an electrochemical biosensor was developed for the highly 
sensitive detection of CA15-3 (LLOQ of 15 µU mL
-1
) in plasma, however, streptavidin-
coated magnetic beads conjugated with biotinylated HRP and biotinylated mAb were used 
as signal enhancer [40]. Thus, those complex amplification strategies have some limitations 
associated, such as laborious and time-consuming procedures, need of expensive chemical 
labels, steric hindrance, among others. By opposition, the developed immunosensor offers 
simplicity of construction and of use and cost-effective and label-free detection, which are 
important advantages over other sensors described in the literature. Still, similar LOD (of 
0.3 U mL
−1
) to the obtained in this work was reported in the literature for the label-free 
electrochemical detection of CA 15-3 based on the catalytic activity of a CuS/rGO 
nanocomposite [41]. Furthermore, the use of low cost and disposable chips, the AuSPEs, 
was another crucial aspect in this work since its combination with simple and compact 
instrumentation allowed the detection of CA 15-3 cancer biomarker in PoC. 
 
 





couple, prepared in 0.1 mol L
-1
 Na2SO4 electrolyte solution, after incubation of the sensor 














) for 30 min. Inset: Calibration curve obtained for CA 15-3 biomarker by using mean value 
± standard deviation (n ≥3). 
Accuracy and reproducibility of the immunosensor was evaluated by repetitive 
measurements performed to build calibration curves, obtained under the same experimental 
conditions on different days. The mean relative standard deviation (RSD) value for 
solutions tested was only 2.8%, indicating that chip surface modification and biosensor 
response was reproducible. Furthermore, low RDS values (<4 %) were reported by our 
research group [42] for repetitive probe measurements at bare AuSPE surface, reinforcing 
that reliable electrochemical immunosensors can be build using ferricyanide/ferrocyanide 
redox probe has reporting system. 
 
3.4 Selectivity study 
 
The quantification of the target biomarker was also performed in the presence of potential 
biological interferents which may be present in real serum samples, such as CA 125  or CA 
19-9 [43]. In this work, the selectivity of the antibody to its antigen was evaluated by 
recording the SPR response (see Fig. S4, SI) for detecting 30 U mL
-1
 CA 15-3 in the 
absence and presence of CA 125 (C = 15 U mL
-1
) and CA 19-9 (C = 25 U mL
-1
), as shown 
in Fig. 5. As can be seen, the sensor response to pure interferent solution was very similar 
to the response obtained for the blank solution. Moreover, the SPR angle variation due to 
CA 15-3 solution was very similar to the recorded for the mixture (CA 15-3 + CA 125 + 
CA 19-9; angle variation was only 7.3%), indicating that the immobilized polyclonal 
antibody was highly selective to the CA 15-3 marker. 
It important to notice that the selectivity of the biosensor was ensured by the antibody 
specific response to the analyte during the first detection step. Thus, possible interferences 
to the electrochemical detection, such as ascorbic acid and other electroactive biomolecules 
that might be present in blood samples, will be wash out from the sensor surface before the 













Fig. 5. Selectivity of the developed immunsensor evaluated by recording the SPR angle 
change after injection on the measuring channel of (i) buffer solution (without CA 15-3 or 
interferent; blank), (ii) buffer solutions containing (I) 15 U mL
-1
 of CA 125, (II) 25 U mL
-1
 
of CA 19-9 and (III) 30 U mL
-1
 of CA 15-3 and a (iii) mixture solution composed of 30 U 
mL
-1
 CA 15-3, 15 U mL
-1
 CA 125 and 25 U mL
-1
 CA 19-9. Error bars indicate the standard 
deviation of the optical signal obtained from triplicate measurements (three independent 
immunoassays for each solution). 
 
3.5 Application to CA 15-3 detection in serum 
 
In this work, detection of CA15-3 in (artificial) serum samples was also performed. The 
developed immunosensor was not applied to real samples due to ethical issues and 
regulatory aspects regarding authorizations that make it difficult to obtain and apply real 
samples in the laboratory context.  Thus, artificial serum with a similar composition of the 












(1:20, in 10 mmol L
-1
 acetate buffer, pH 4.0) prior the measurements to minimize matrix 
effects.  
Data obtained from electrochemical experiments allowed to build the assay calibration 
curve (see Fig. S5, SI). Then, the estimated analytical features of the immunosensor in 
serum were compared with the obtained in buffer solution in terms of detection sensitivity, 
LODs achieved, linear concentration ranges, etc. (see Table S3, SI). Although the results 
showed a decrease of detection sensitivity (of about 29%) relatively to buffer solution, 
probably due to non-specific binding of serum proteins to the sensor surface, the 
immunosensor kept the same linear concentration range (1.0 - 1000 U mL
-1
) and similar 
LODs were archived, indicating that the developed immunosensor was suitable for 
quantification of the CA 15-3 biomarker in the prepared serum samples. 
The applicability of the proposed sensor was assessed by the recovery study. To perform 
these studies, blank artificial serum samples were spiked with known amounts of CA 15-3 
(from 0.30 to 50 U mL
-1
) for evaluation of the immunosensor response. The results 
obtained for three samples in triplicate with different concentration levels are summarized 
in Table 1. The results showed that there was a good relationship between added and found 
amounts of CA15-3 and detection recoveries between 93.3 % and 106.8 % were achieved 
(average relative error of 5.4 %). Thus, in our opinion, the improved performance of the 
developed immunosensor indicates that it can be successfully applied for the detection of 
CA 15-3 in real biofluids in clinical setting. 
 











Relative error  
(%) 
1 3.0 3.2 ± 0.5 107 ± 7 -6.7 
2 30 30 ± 3 99 ± 8 1.3 















In this work, we have developed and optimized an amperometric immunosensor for simple 
and rapid screening of CA15-3 biomarker, in PoC, being a valuable resource under clinical 
setting for the early diagnosis of breast cancer disease. Low-cost and disposable chips, the 
AuSPEs, were used to build the electrochemical device since it combines properties of 
good biocompatibility, ease of use, portability (compatible with PoC testing) and low 
sample volume for detection. 
The biosensing platforms were prepared by simple and efficient immobilization of CA 15-3 
antibody over a pre-formed MSA SAM. They were able to detect and quantify the tumor 
marker by performing electrochemical measurements upon cumulative immunecomplex 
formation at the sensor surface, which continuously hinders the diffusional redox probe 
behavior at the electrode surface. 
The developed immunosensor presented improved performance and good analytical 
features were achieved, namely: (i) wide dynamic concentration linear range (from 1.0 to 
1000 U mL
-1
) for easy detection of CA 15-3 levels below and above cut-off value; (ii) good 
selectivity towards CA 15-3, allowing its detection in the presence of co-existing cancer 
biomarkers (CA 125 and CA 19-9) in serum samples; (iii) low detections levels were 
achieved (LOD of 0.60 U mL
-1
), allowing the quantification of the biomarker in artificial 
serum at clinically relevant levels.  
In our opinion, the high sensitivity (and selectivity) of the developed electrochemical 
device makes it suitable to be applied to the analysis of CA15-3 in real serum samples, in 
clinical context. Besides, the label-free, simple and cost-effective detection has unique 
advantages over classical immunosensors, most of times having tedious and complex 
procedures and/or requiring expensive tags (secondary antibodies, conjugated or not with 
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